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Abstract
Introduction:  Non-heritable factors may have an influence on the clinical expression of
monogenic inherited metabolic diseases.
Case presentation: This is a case report of a man whose mother had been diagnosed late in
childhood with pyridoxine responsive homocystinuria with lens dislocation and
neurodevelopmental delay. These severe complications were not observed in her son who was
pyridoxine unresponsive but who had been treated appropriately since early infancy.
Conclusion: The phenotype of people with homocystinuria can be discordant within a family, with
variability in metabolic and clinical expression depending upon both the genotype and therapeutic
interventions. Offspring of people with homocystinuria should be screened in early infancy and, if
positive, treated appropriately whether they have pyridoxine responsive or unresponsive disease.
Background
Homocystinuria is an inherited recessive disorder due to
cystathionine beta-synthase (CBS) deficiency, with a wide
spectrum of clinical manifestations involving ocular lens
dislocation, skeletal disproportion, osteoporosis, vascular
thromboses and central nervous system dysfunction. We
report a familial discordance of phenotype between a
mother and her son, both affected with homocystinuria,
to illustrate powerful environmental influences on the
metabolic phenotype.
Case presentation
Our patient, born in 1986, was the second son of a
woman who had had progressive loss of vision during the
first 7 years of her life, related to bilateral dislocated
lenses. She was diagnosed with homocystinuria when
both lenses were surgically removed when she was 7 years
old. Plasma free homocystine and methionine were 48
µmol/l (N = 0) and 670 µmol/l (N = 19–25), respectively.
She had moderate learning difficulties, a depressed ster-
num, pes cavus, high arched palate, fair skin with easily
seen veins and signs of osteoporosis on spinal X-rays. She
had neither arachnodactyly nor thromboembolic events.
She was initially and successfully treated with pyridoxine
500 mg/day, which was reduced to 100 mg/day and then
50 mg/day.
At age 24 years, she had a normal pregnancy giving birth
to an unaffected child, without post-partum complica-
tions. At age 29 years, she had a male child by a different
unrelated partner. The plasma total homocysteine (tHcy)
in this child was elevated at 107 µmol/l (N = 5–15). Fol-
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low-up of the mother between the ages of 29 and 48 years
showed satisfactory metabolic control (plasma tHcy 21 –
112 µmol/l, plasma methionine 45–48 µmol/l) with ther-
apy including pyridoxine 50 mg/day, folic acid 5 mg/day,
cyanocobalamin 50 µg/day and an unrestricted diet. No
new clinical events have occurred, despite the fact she was
a mild smoker. Molecular study of the CBS gene showed
the mutations c.374 G>A (R125Q) in exon 3 and c.671
G>T (R224L) in exon 6.
The second child of our patient was seen at the age of 17
days for homocystinuria screening. His father had no fam-
ily history of homocystinuria. At the age of 17 days, free
Hcy was not detected but 8 months later plasma tHcy and
methionine were 107 and 1999 µmol/l, respectively. A
methionine-restricted diet was started, with pyridoxine 50
mg/day and folic acid 5 mg/day. Between the age of one
and nine years, metabolic control was good with plasma
tHcy less than 5–13 µmol/l, methionine 46–53 µmol/l,
growth was normal and no lens dislocation was observed.
The patient had no arachnodactyly, no bone deformities
and his neurological development was normal. At age 10
years, betaine 3 g/day was started. From age 13 to 19 years,
plasma tHcy and methionine mostly remained high, at
100–201 and 636–708 µmol/l respectively, despite
increasing doses of pyridoxine to 300 mg/day, betaine to
4.5 g/day and adding cyanocobalamin 50 µg/day. No clin-
ical events were reported and eye examination remained
normal despite suspected non-compliance with therapy.
At age 19 years, his DEXA lumbar spine Z-score was -2.7.
Molecular analysis of the CBS gene showed the mutations
c374 G>A (R125Q) and c.689 insC, which predicts a
frameshift and downstream stop codon.
Discussion and conclusion
For the mother, a low dose of pyridoxine was able to
maintain a satisfactory plasma tHcy without dietary
methionine restriction. This indicates that she had pyri-
doxine responsive homocystinuria. Patients homozygous
for the R125Q mutation have been previously described
as pyridoxine non-responsive [1] or partially pyridoxine
responsive if associated with the severe phenotype [2].
Thus, the case of the patient's mother suggests that R125Q
mutation in one copy, in association with another mis-
sense mutation (R224L), does not result in pyridoxine
non-responsiveness. Moreover, we think that her severe
phenotype was more related to late diagnosis than her
genotype. Her son did not inherit her pyridoxine respon-
siveness as a high dose of pyridoxine was unable to signif-
icantly reduce plasma tHcy [3]. He carried a novel, severe
and pathogenic mutation (c.689 insC) of the CBS gene, in
association with the maternally inherited R125Q, which
resulted in a pyridoxine non-responsive homocystinuria.
It is also likely that, after a period of good metabolic con-
trol during childhood, he failed to maintain a methio-
nine-restricted diet in the teenage years, a potential
problem encountered in adolescence during the follow-
up of many patients with inborn errors of metabolism [4].
In most patients, pyridoxine responsiveness is based on
the presence of residual activity of mutant CBS, which
have been closely linked to CBS mutations [5]. For exam-
ple, the frequent G370S mutation, in one or two copies,
appears to be incompatible with pyridoxine responsive-
ness, producing a severe phenotype [1]. Conversely, the
I278T mutation usually confers pyridoxine responsive-
ness, whether in homozygotes or compound heterozy-
gotes [6]. In the case presented here, the son has inherited
a severe pyridoxine non-responsive mutation from his
father who presumably was a heterozygous carrier of this
mutant CBS allele. It has been shown that an identical
CBS genotype does not always result in the same pheno-
type, even within a family, and although pyridoxine
responsiveness is absolutely constant within sibships, the
clinical phenotype is often not [5]. This indicates that
non-heritable factors may influence the clinical expres-
sion of homocystinuria in genetically predisposed indi-
viduals.
Beyond the genotype-phenotype correlation, the homo-
cystinuria described in this family shows that a maximal
benefit from therapy may be expected when the disorder
is detected in early infancy. Although it is generally recog-
nized that pyridoxine responsive patients are more mildly
affected than non-responsive patients, the cases reported
here show that a methionine restriction diet started early
can prevent or delay a number of important complica-
tions of CBS deficiency, in particular neurodevelopment
and lens dislocation. This is consistent with previous data
showing that patients carrying the G307S mutation seem
to have moderate to severe phenotypes, except for those
treated from birth [5]. Newborn screening and early treat-
ment for phenylketonuria dramatically alters the clinical
phenotype and our cases mirror this. We recommend that
offspring of people with homocystinuria should be
screened early in infancy and if positive, treated appropri-
ately whether they have pyridoxine responsive or unre-
sponsive disease.
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